In a report released on February 23, Marc Goodman from SVB Securities reiterated a Buy rating on Opthea Limited Sponsored ADR (OPT – Research Report), with a price target of $25.00. The company’s shares closed last Friday at $5.04.
Goodman covers the Healthcare sector, focusing on stocks such as Biogen, Evolus, and Marinus. According to TipRanks, Goodman has an average return of 2.3% and a 46.09% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Opthea Limited Sponsored ADR with a $14.00 average price target, a 178.05% upside from current levels. In a report released on February 24, H.C. Wainwright also reiterated a Buy rating on the stock with a $14.00 price target.
See the top stocks recommended by analysts >>
Based on Opthea Limited Sponsored ADR’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $0. In comparison, last year the company had a net profit of $0
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea’s development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Read More on OPT:
- Opthea announces publication of Phase 2b trial results of OPT-302
- Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology
- Opthea To Present at SVB Leerink Global Biopharma Conference
- Opthea To Present at Sequire Biotechnology Conference
